Expert oncologists identify molecular targets in breast cancer and review available testing platforms in the current treatment paradigm.

Shared insight on next-generation sequencing platforms, plasma- and tumor-based, for patients with late-stage HR+ breast cancer.

Comprehensive insight on trial data from OlympiA, which utilized adjuvant olaparib therapy in patients with gBRCA1/2 mutated breast cancer.

Focusing on high-risk HR+/HER2- breast cancer, key opinion leaders review data with adjuvant abemaciclib from the monarchE clinical trial.

Expert perspectives on the KEYNOTE-522 clinical trial, which utilized adjuvant pembrolizumab following neoadjuvant pembrolizumab plus chemotherapy in TNBC.

A brief review of the value of using brain MRI to help determine treatment approaches for patients with HER2+ metastatic breast cancer.

Comprehensive discussion on the DESTINY-Breast03 clinical trial evaluating trastuzumab deruxtecan in patients with previously treated HER2+ metastatic breast cancer.

Focusing on the HER2CLIMB trial in HER2+ metastatic breast cancer, expert oncologists consider the value of a tucatinib-based regimen in this setting.

Expert perspectives on the use of trastuzumab deruxtecan in HER2-low metastatic breast cancer in the context of the DESTINY-Breast04 trial.

A brief review of data from the TROPiCS-02 clinical trial, which evaluated sacituzumab govitecan in HR+/HER2- metastatic or inoperable breast cancer.

Closing out the discussion on molecular targets and clinical trials in breast cancer, expert oncologists take time to field questions from the live audience.